OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.
Key Takeaways
- The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.
- Read the full article for additional context and details.
- Read the full article for additional context and details.
Summary generated by IndiCrypto from Decrypt. IndiCrypto is a news aggregator and does not provide investment advice. Read the original article for full context.
More in AI x Crypto
U.S. CFTC sets agenda for AI forum, exploring trading and agentic finance
A Commodity Futures Trading Commission task force is scheduled for October 28 to talk about how the latest "super intelligence" technology may impact markets.
SpaceX Beats Q3 2026 Estimates as Revenue Surges 161% YoY
SpaceX reported third-quarter 2026 results after the market closed on October 20, with revenue up 161% YoY. The growth was led by its Super Intelligence segment. Heavy capital spending remains the central question for investors. Here is what the numbers show.…
US orders DeepSeek purge from federal systems as Chinese AI rival opens its technology to the world
The October 20 notice covers tools built using DeepSeek implementations, with a 60-day exception period tied to July issuance. Read the full story on CryptoSlate Understand the crypto stories that matter and what to watch next. Get The Catalyst in your inbox